vs
Side-by-side financial comparison of JOINT Corp (JYNT) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $9.1M, roughly 1.7× Protalix BioTherapeutics, Inc.). JOINT Corp runs the higher net margin — 6.5% vs -60.3%, a 66.9% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $334.7K). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -28.6%).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
JYNT vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $9.1M |
| Net Profit | $991.1K | $-5.5M |
| Gross Margin | 81.4% | 49.4% |
| Operating Margin | 4.9% | -51.1% |
| Net Margin | 6.5% | -60.3% |
| Revenue YoY | 3.1% | -49.9% |
| Net Profit YoY | 5510.5% | -184.8% |
| EPS (diluted) | $0.06 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.2M | $9.1M | ||
| Q3 25 | $13.4M | $17.9M | ||
| Q2 25 | $13.3M | $15.7M | ||
| Q1 25 | $13.1M | $10.1M | ||
| Q4 24 | $14.7M | $18.2M | ||
| Q3 24 | $30.2M | $18.0M | ||
| Q2 24 | $30.3M | $13.5M | ||
| Q1 24 | $29.7M | — |
| Q4 25 | $991.1K | $-5.5M | ||
| Q3 25 | $855.0K | $2.4M | ||
| Q2 25 | $93.4K | $164.0K | ||
| Q1 25 | $967.8K | $-3.6M | ||
| Q4 24 | $17.7K | $6.5M | ||
| Q3 24 | $-3.2M | $3.2M | ||
| Q2 24 | $-3.6M | $-2.2M | ||
| Q1 24 | $947.0K | — |
| Q4 25 | 81.4% | 49.4% | ||
| Q3 25 | 80.1% | 53.4% | ||
| Q2 25 | 79.1% | 62.5% | ||
| Q1 25 | 77.3% | 19.1% | ||
| Q4 24 | 78.4% | 78.7% | ||
| Q3 24 | 90.7% | 53.4% | ||
| Q2 24 | 90.7% | 29.8% | ||
| Q1 24 | 90.9% | — |
| Q4 25 | 4.9% | -51.1% | ||
| Q3 25 | 1.2% | 11.9% | ||
| Q2 25 | -8.6% | 7.5% | ||
| Q1 25 | -5.2% | -41.0% | ||
| Q4 24 | 5.5% | 39.6% | ||
| Q3 24 | -1.6% | 22.2% | ||
| Q2 24 | -5.9% | -18.0% | ||
| Q1 24 | -1.4% | — |
| Q4 25 | 6.5% | -60.3% | ||
| Q3 25 | 6.4% | 13.2% | ||
| Q2 25 | 0.7% | 1.0% | ||
| Q1 25 | 7.4% | -35.8% | ||
| Q4 24 | 0.1% | 35.6% | ||
| Q3 24 | -10.5% | 18.0% | ||
| Q2 24 | -11.9% | -16.4% | ||
| Q1 24 | 3.2% | — |
| Q4 25 | $0.06 | $-0.06 | ||
| Q3 25 | $0.06 | $0.03 | ||
| Q2 25 | $0.01 | $0.00 | ||
| Q1 25 | $0.06 | $-0.05 | ||
| Q4 24 | $0.01 | $0.10 | ||
| Q3 24 | $-0.21 | $0.03 | ||
| Q2 24 | $-0.24 | $-0.03 | ||
| Q1 24 | $0.06 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.1M | $48.2M |
| Total Assets | $61.0M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $14.7M | ||
| Q3 25 | $29.7M | $13.6M | ||
| Q2 25 | $29.8M | $17.9M | ||
| Q1 25 | $21.9M | $19.5M | ||
| Q4 24 | $25.1M | $19.8M | ||
| Q3 24 | $20.7M | $27.4M | ||
| Q2 24 | $17.5M | $23.4M | ||
| Q1 24 | $18.7M | — |
| Q4 25 | $15.1M | $48.2M | ||
| Q3 25 | $22.7M | $52.9M | ||
| Q2 25 | $23.2M | $49.9M | ||
| Q1 25 | $22.8M | $45.2M | ||
| Q4 24 | $20.7M | $43.2M | ||
| Q3 24 | $20.5M | $32.4M | ||
| Q2 24 | $23.2M | $28.6M | ||
| Q1 24 | $26.2M | — |
| Q4 25 | $61.0M | $82.3M | ||
| Q3 25 | $69.4M | $82.3M | ||
| Q2 25 | $73.2M | $78.5M | ||
| Q1 25 | $80.1M | $73.9M | ||
| Q4 24 | $83.2M | $73.4M | ||
| Q3 24 | $79.6M | $61.6M | ||
| Q2 24 | $82.4M | $91.5M | ||
| Q1 24 | $85.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $2.0M |
| Free Cash FlowOCF − Capex | $334.7K | $1.6M |
| FCF MarginFCF / Revenue | 2.2% | 17.8% |
| Capex IntensityCapex / Revenue | 9.9% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $2.0M | ||
| Q3 25 | $1.8M | $-3.7M | ||
| Q2 25 | $868.6K | $-5.2M | ||
| Q1 25 | $-3.7M | $-5.1M | ||
| Q4 24 | $9.4M | $4.0M | ||
| Q3 24 | $3.4M | $4.1M | ||
| Q2 24 | $-973.5K | $-3.6M | ||
| Q1 24 | $2.8M | — |
| Q4 25 | $334.7K | $1.6M | ||
| Q3 25 | $1.5M | $-4.2M | ||
| Q2 25 | $363.6K | $-5.7M | ||
| Q1 25 | $-4.0M | $-5.4M | ||
| Q4 24 | $8.2M | $3.6M | ||
| Q3 24 | $3.2M | $4.0M | ||
| Q2 24 | $-1.2M | $-3.8M | ||
| Q1 24 | $2.4M | — |
| Q4 25 | 2.2% | 17.8% | ||
| Q3 25 | 10.9% | -23.7% | ||
| Q2 25 | 2.7% | -36.2% | ||
| Q1 25 | -30.8% | -53.0% | ||
| Q4 24 | 55.9% | 19.6% | ||
| Q3 24 | 10.6% | 22.4% | ||
| Q2 24 | -4.1% | -28.1% | ||
| Q1 24 | 8.1% | — |
| Q4 25 | 9.9% | 4.4% | ||
| Q3 25 | 2.4% | 2.8% | ||
| Q2 25 | 3.8% | 2.8% | ||
| Q1 25 | 2.5% | 3.0% | ||
| Q4 24 | 8.1% | 2.3% | ||
| Q3 24 | 0.8% | 0.5% | ||
| Q2 24 | 0.9% | 1.3% | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.86× | — | ||
| Q3 25 | 2.07× | -1.58× | ||
| Q2 25 | 9.30× | -31.91× | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
